Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

By Ben Fidler • Oct. 5, 2026

3 takeaways from a European obesity scientific meeting

Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

By Jonathan Gardner • Oct. 1, 2026

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

HHS kicks off new programs to speed clinical trials as Chinese competition looms

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

By Kristin Jensen • Oct. 1, 2026

Pfizer’s eczema drug clears skin in mid-stage trial

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

By Delilah Alvarado • Oct. 1, 2026

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

By Jonathan Gardner • Sept. 30, 2026

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

By Jonathan Gardner • Sept. 28, 2026

An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus

Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.

By Gwendolyn Wu • Sept. 28, 2026

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

By Kristin Jensen • Sept. 24, 2026

Roche, Ionis RNA drug scores in kidney disease study

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

By Jonathan Gardner • Sept. 23, 2026

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

By Gwendolyn Wu • Sept. 22, 2026

Viking shares surge on updated obesity drug data

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

By Jonathan Gardner • Sept. 22, 2026

Celldex sinks as safety concerns cloud immune drug results

Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

By Kristin Jensen • Sept. 22, 2026

Beacon eye gene therapy hits mark in late-stage study

Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

By Gwendolyn Wu • Sept. 21, 2026

Xenon shares fall following depression trial pause

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

By Jonathan Gardner • Sept. 18, 2026

Skyhawk racks up more support for Huntington’s drug

The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

By Jacob Bell • Sept. 16, 2026

WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

By Ben Fidler , Jonathan Gardner • Sept. 15, 2026

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

By Jonathan Gardner • Sept. 14, 2026

AstraZeneca’s newly approved pill fails frontline breast cancer study

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

By Delilah Alvarado • Sept. 14, 2026

Tyra disappoints investors with bladder cancer data

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

By Jonathan Gardner • Sept. 9, 2026

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

By Jacob Bell • Sept. 8, 2026

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

By Ben Fidler • Sept. 5, 2026

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

By Jonathan Gardner • Sept. 4, 2026

Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.

By Kristin Jensen • Sept. 3, 2026

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

By Jonathan Gardner • Sept. 3, 2026

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

By Delilah Alvarado • Sept. 1, 2026